Download Delivering on the Antimicrobial Resistance (AMR) agenda is not

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Delivering on the Antimicrobial Resistance (AMR) agenda is not possible
without improving fungal diagnostic capabilities
David W. Denning1,2, David. S. Perlin2,3, Eavan G. Muldoon1, Arnaldo Lopes
Colombo2,4, Arunaloke Chakrabarti2,5, Malcolm D. Richardson2.6 and Tania C.
Sorrell2,7
1
The National Aspergillosis Centre, University Hospital of South Manchester, The
University of Manchester, Manchester Academic Health Science Centre, Manchester,
UK
2
Global Action Fund for Fungal Infections, Geneva, Switzerland;
3
Public Health Research Institute, Rutgers Biomedical and Health Sciences, Newark,
NJ, USA;
4
Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo,
Brazil.
5
Center of Advance Research in Medical Mycology, Postgraduate Institute of
Medical Education & Research, Chandigarh 160012, India
6
Mycology Reference Centre, Manchester; Manchester Academic Health Science
Centre; University Hospital of South Manchester, Manchester and International
Society for Human and Animal Mycology
7
Marie Bashir Institute for Infectious Diseases & Biosecurity, University of Sydney,
Australia.
*Correspondence:
34
Professor David Denning
35
National Aspergillosis Centre, Education and Research Centre, University Hospital of
36
South Manchester, Southmoor Road, Manchester M23 9LT
37
Tel.: +44 161 291 5811
38
E-mail: [email protected]
39
40
41
42
43
44
45
46
One line summary: Widespread use of accurate and sensitive fungal diagnostic testing
will reduce unnecessary antibacterial and antifungal therapy
Key words: Aspergillus, Candida, Pneumocystis, Histoplasma, Cryptococcus,
resistance
Word count: 2196
1
47
ABSTRACT
48
Antimicrobial resistance (AMR) is a major public health concern largely arising from
49
the excess use of antibacterial and antifungal drugs. Here we argue that the lack of
50
routine fungal disease diagnostic testing exacerbates the problem of antimicrobial
51
empiricism, both antibiotic and antifungal. We cite 4 common clinical situations that
52
are illustrative. 1. Accurate diagnosis of fungal sepsis in the hospital and the
53
Intensive Care Unit to reduce the use of broad-spectrum antibacterial therapy
54
administered inappropriately to patients with invasive candidiasis. 2. Failure to
55
diagnose smear-negative pulmonary ‘tuberculosis’ as chronic pulmonary
56
aspergillosis. 3. Mis-diagnosing ‘fungal asthma’ that results in unnecessary courses of
57
antibiotics instead of antifungals and missing life-threatening invasive aspergillosis in
58
COPD patients. 4. Both over- and under-treatment of Pneumocystis jirovecii
59
pneumonia in HIV positive patients. All communities should have access to non-
60
culture fungal diagnostics, which will have a substantial benefit for clinical outcome,
61
antimicrobial stewardship and AMR control.
62
63
2
64
Antimicrobial resistance (AMR) is a significant public health concern, and a major
65
threat to modern medicine (1). It is estimated that in the United States antibiotic
66
resistant infections are associated with 23,000 deaths per year (2), and that excess
67
healthcare costs are in the region of US $20-25 billion (3). Minimizing AMR has been
68
the focus of accelerating efforts with multi-pronged approaches tailored to individual
69
countries and healthcare settings. Even if the difficult task of developing new
70
antimicrobials is successful, current efforts aimed at reducing the development of
71
resistance will need to be maintained to protect these novel compounds.
72
A central tenet of controlling AMR is antibiotic stewardship, which seeks to limit
73
inappropriate antibiotic usage either by avoiding unnecessary prescribing or
74
discontinuing antibiotic therapy immediately it is not required. Within the context of
75
stewardship programs, inadequate attention has been paid to fungal infection as the
76
cause of antibacterial treatment failure. Furthermore the importance of accurate and
77
timely diagnosis of fungal infection in defeating AMR has been starkly absent from
78
policy discussions (4). Accurate diagnosis or exclusion of fungal infection impacts
79
substantially on antimicrobial usage and our ability to limit bacterial AMR.
80
Generally, physicians prescribe most antimicrobials empirically as very few
81
infections are microbiologically diagnosed in real time. Further, most infections are
82
never microbiologically documented, which matters little if the patient improves and
83
infection resolves, but leads to additional empirical antimicrobial use if the patient
84
deteriorates (5). Fungal infections are often undiagnosed and untreated, and they are
85
a frequent fatal complication (superinfection) of numerous diseases (cancer, liver,
86
respiratory and/or renal failure, sepsis, AIDS etc) that contribute to inappropriate
87
antibiotic usage. This must stop.
88
We provide four specific clinical examples where we argue for greater application
89
of existing fungal diagnostics and improved overall fungal diagnostic capability in
90
line with the recently issued ’95-95 by 2025’ Roadmap from the Global Action Fund
91
for Fungal Infections (6).
92
93
Accurate diagnosis of fungal sepsis in hospital and Intensive Care Unit (ICU)
94
Hospitalized patients, especially those in the ICU, are often inappropriately placed on
95
broad-spectrum antibiotics because fungal diseases involving Candida spp are not
96
diagnosed. Bloodstream infection and invasive candidiasis are substantially more
97
common than appreciated. Multiple factors are likely to be responsible, including
3
98
unrestrained antibiotic use, indwelling devices, increasing populations of
99
immunocompromised patients, increased renal support and others. Bloodstream
100
infections with Candida spp. have a population incidence of 1.2-26/100,000 in
101
multiple studies, with the highest rates in middle- and high-income countries, notably
102
the USA (7,8). Most (93%) of episodes are healthcare-associated (~80% as inpatients)
103
and 7% are community acquired (9). In Brazil, with a population of 194 million,
104
Candida bloodstream infections are seen in 14.9/100,000 population, or 29,000
105
people each year (10), based on prospective data obtained 10 years ago from 11
106
medical centres (11). A recent prospective study from 27 ICUs in India found a mean
107
incidence of 6.51 cases of ICU-acquired candidemia per 1,000 ICU admissions with
108
a 35-75% mortality (12). An estimated 14.3 million patients are admitted to ICUs in
109
India each year. Undoubtedly this high rate underestimates the problem, as blood
110
culture is only ~40% sensitive for invasive candidiasis (including intra-abdominal
111
candidiasis), with fluconazole and echinocandins substantially reducing the yield from
112
blood culture (13-15). It is likely therefore that the actual burden and death rate in
113
ICU exceeds 200,000 patients and ~100,000 deaths. If, as is found in other countries,
114
Candida bloodstream infection (and presumably invasive candidiasis) outside ICUs is
115
at least twice as common as in ICUs, over 600,000 patients are estimated to have
116
invasive candidiasis in India each year, with ~300,000 deaths, assuming patients are
117
treated, and many more if not.
118
In addition, a high prevalence of candidemia has been reported in children and
119
neonates in India and Latin America. Central nervous system involvement is quite
120
common in premature infants leading to a high rate of neurological sequelae (16).
121
While invasive candidiasis is strongly associated with prior bacterial infection and
122
anti-bacterial therapy, inappropriate escalation and combination antibacterial therapy
123
will typically have been administered to patients with invasive candidiasis. In one
124
large study of 444 patients with Candida bloodstream infections, 81% were exposed
125
to multiple antibacterial drugs, either concomitantly or sequentially (17) and in the
126
ICU study from India described above, 95% were already on antibiotics, usually two
127
or more (12). Early therapy of Candida bloodstream infection greatly improves
128
patient outcomes as shown in several observational studies, and even better if
129
‘correct’ therapy is given immediately (18).
130
131
Once Candida sepsis is confirmed, antibacterial agents can usually be stopped and,
if ruled out, empirical antifungal therapy can be stopped. Inflammation without
4
132
infection requires no antimicrobial therapy. Three well-validated diagnostic tools, two
133
configured for ruling out a diagnosis of invasive candidiasis, are now available - the
134
1,3 beta-D-glucan assay (19), the Candida albicans germ tube antibody test
135
(CAGTA) (serum samples) (20) and a newly FDA approved nonculture-based
136
molecular assay which is substantially more sensitive than blood culture and useful
137
for making the diagnosis Candida (EDTA blood) (21). In patients without invasive
138
candidiasis, antimicrobial stewardship programs based on such diagnostics have
139
successfully curtailed the use of antifungal therapy in the ICU without worsening
140
patient outcomes (18,22). The economics depend on the cost of diagnostic reagents
141
and testing, antifungal costs and incidence of infection (23). Overuse of antifungal
142
agents is very costly and can promote antifungal resistance, may carry toxicity and the
143
potential for numerous detrimental drug interactions (18). Modeling will be required
144
to determine the magnitude of the impact on antibacterial prescribing. What is not in
145
dispute is that patient outcomes for those with fungal infection will improve.
146
Antimicrobial stewardship programs will be even more effective if these diagnostic
147
tools, with their rapid turnaround times, are readily available (24). Widespread
148
implementation of rapid non-culture Candida diagnostics will greatly improve
149
prescribing practices for the complex hospital patient.
150
151
Mis-diagnosis of smear-negative pulmonary ‘tuberculosis’ as tuberculosis
152
Smear-negative pulmonary tuberculosis (TB) is a problematic area for clinicians
153
and policy makers. Post-tuberculous sequelae are common, poorly studied and may be
154
mistaken for active, recurrent TB (25), and it is apparent that an important under-
155
recognised issue for these patients is chronic pulmonary aspergillosis (CPA), which
156
can mimic TB presentation. Among 544 patients previously treated for TB, with a
157
residual cavity, in the UK, 34% developed precipitating antibodies to Aspergillus
158
fumigatus of whom 63% developed aspergilloma within 2 years (a late stage of
159
chronic pulmonary aspergillosis) and 42% of these patients developed hemoptysis
160
(26). Prospective studies of CPA (after treatment for TB) are otherwise lacking, but
161
conservatively an assumed rate of ~10% is likely, with ~1.2 million individuals
162
affected (26).
163
Culture of Mycobacterium tuberculosis from smear-negative patients is slow and
164
may be falsely negative. The use of new, highly sensitive, DNA detection assays (e.g.
165
Xpert MTB/RIF) directly on respiratory specimens has transformed the rapidity of
5
166
detecting positive results, but there remains a considerable proportion of unwell,
167
smear negative, PCR-negative patients. Some of these are patients who have
168
‘relapsed’ following anti-tuberculous therapy have CPA. Those with ‘smear-negative
169
TB’ and HIV infection, have a higher mortality than smear positive patients (27),
170
probably because many do not have TB at all. It is increasingly being recognized that
171
many of these patients are chronically infected with Aspergillus spp. resulting in CPA
172
that is largely undiagnosed and untreated.
173
Weight loss, worsening cough, chest pains, dyspnea and fatigue are common to TB
174
and CPA, and the radiological abnormalities are similar (Figure 1). In studies from the
175
UK, Brazil, Korea, Iran and India, the frequency of elevated Aspergillus serum
176
antibody after TB varied upwards from 20% (28,29. Aspergillus antibody detection is
177
the key diagnostic test for CPA, and performs well (96-97% sensitivity, 92-98%
178
specificity (30,31), compared with controls. Given that CPA is a common sequel to
179
TB and has a 5-year mortality of 75-80%, it needs to be sought actively using
180
antibody testing (32). Sera from almost all patients with ‘recurrent TB’ in Iran were
181
Aspergillus antibody positive (33). Pneumocystis jirovecii DNA was identified in the
182
sputum of up to 7% of patients with smear-negative TB in Brazil and 6.7% in
183
Uganda, providing an alternative, potentially treatable diagnosis, and there are others
184
such as histoplasmosis (Figure 2) and coccidioidomycosis (5).
185
Empirical anti-tuberculous therapy is unnecessary in patients with either chronic
186
pulmonary aspergillosis or other fungal infections, as it is ineffective and exposes the
187
patient to potential toxicity. Yet, it remains the default approach for most complicated
188
TB patients. When such treatment fails, as it usually does, there is a risk that patients
189
are assumed to have multidrug resistant (MDR) TB, and the inappropriate substitution
190
of second and third line anti-tuberculous agents adds to potential toxicities and
191
healthcare costs. The size of the problem is substantial with the WHO reporting
192
2,755,870 patients with smear negative TB in 2013 (34). Aspergillus antibody
193
detection should be widely available and integrated into TB control programs with
194
CPA as post-TB sequelae emphasised. All symptomatically recurrent TB cases should
195
be screened for Aspergillus antibody.
196
197
Fungal exacerbations of asthma and chronic obstructive airways disease (COPD)
198
It is common practice in the community to treat asthma and exacerbations of
199
COPD with antibiotics and corticosteroids, although guidelines caution against
6
200
unnecessary use, especially in COPD patients (35). Most patients respond, even if the
201
exacerbation is virus-induced. Patients with moderate and severe COPD are
202
frequently admitted to hospital and have an in-hospital mortality of 6%. The majority
203
patients (>80%) are treated with antibiotics (36), although multiple guidelines advise
204
against this in the absence of purulent sputum and pulmonary infiltrates. It is now
205
well established that Aspergillus airways colonization (or infection) is strongly
206
associated with exacerbations (37). Two studies have addressed the frequency of
207
invasive aspergillosis in these patients - with a 1.3% rate in Spain (38) and a 3.9% rate
208
in southern China (39), based on sputum cultures revealing Aspergillus spp (which
209
likely under-estimates the problem as Aspergillus culture is insensitive). The
210
respective mortality rates were 65% and 43%. Most are not treated for invasive
211
aspergillosis but are treated unnecessarily with antibiotics. The scale of the problem is
212
large: In China, 87 per 10,000 people over 40 years of age (an estimated 11,858,000)
213
COPD patients were admitted to hospital in 2012 (40,41), ~462,000 may have
214
developed invasive aspergillosis and ~200,000 may have died. Presumably other
215
countries with high COPD rates such as Hungary, Ireland, and New Zealand face a
216
similar situation.
217
Asthmatics with frequent exacerbations and/or poorly controlled disease may take
218
several antibiotic courses a year and some are managed with long-term antibiotics.
219
Recently, awareness and understanding of ‘fungal asthma’ has increased and a timely
220
diagnosis and the use of antifungal therapy could substantially reduce antibiotic
221
prescriptions. Long-term antifungal therapy is efficacious in 60-80% of patients with
222
fungal asthma, notably allergic bronchopulmonary aspergillosis (ABPA) and severe
223
asthma with fungal sensitisation (SAFS) (42). Both antibiotic and corticosteroid use
224
fall with successful antifungal therapy and may reduce hospitalization.
225
Diagnosis of fungal asthma relies on total and fungal specific IgE testing, or skin
226
prick testing which is simple to do, yet not often done. Rapid antigen detection with a
227
lateral flow device might accelerate diagnosis, although no data are published on
228
utility for sputum, or on COPD patients. Few studies have addressed the role of fungi
229
in precipitating exacerbations of COPD, although culture, antigen and Aspergillus IgG
230
antibody all contribute to the diagnosis of chronic and invasive aspergillosis.
231
Failure to properly diagnose and treat fungal asthma and COPD patients with
232
Aspergillus colonisation continues to increase the inappropriate use of antibiotics (and
233
corticosteroids) among these patients. Recognition of fungal infection and/or allergy
7
234
with directed antifungal therapy would greatly reduce exacerbations, medical
235
consultations and hospital admissions. There is an urgent need to evaluate and
236
implement both fungal culture and non-culture diagnostics (Aspergillus IgE,
237
Aspergillus IgG, Aspergillus antigen and PCR) for COPD and asthma exacerbations,
238
and to diagnose fungal asthma and treat it with antifungals.
239
240
241
Making and excluding the diagnosis of Pneumocystis pneumonia in AIDS
Pneumocystis pneumonia (PCP) in AIDS is often diagnosed empirically based on a
242
subacute onset of cough, breathlessness out of proportion to the radiological
243
abnormalities and subtle, bilateral chest X-ray changes, in the context of a low CD4
244
cell count (Figure 3). Co-trimoxazole (trimethoprim-sulphamethoxazole, Bactrim®,
245
Septrin®) is the most effective agent for both prevention and therapy of PCP. A low
246
dose is effective for prophylaxis, but a 3-week course of high and potentially toxic
247
doses is required for effective therapy. The differential diagnosis of PCP is broader in
248
children as bacterial pneumonia is more common. If a precise diagnosis could be
249
achieved in most cases of PCP, much inappropriate use of co-trimoxazole would be
250
prevented.
251
Rates of PCP among newly hospitalized adults with advanced HIV infection are
252
highly variable (<1% to 60%), with rising rates as gross domestic product increases
253
(43). Without adequate diagnostics available, many patients will unnecessarily
254
receive high dose co-trimoxazole with or without corticosteroids for 3 weeks. If the
255
actual number of PCP cases in patients with AIDS is 400,000, then 100,000s may be
256
given co-trimoxazole unnecessarily, with toxicity rates as high as 90% (5,44). Early
257
detection and diagnosis of PCP can help prevent unnecessary hospitalization and cost.
258
Currently bronchoscopy and microscopic examination of bronchoalveloar lavage fluid
259
is the commonest definitive means of establishing the diagnosis, with a sensitivity of
260
75-90% depending on the microscopy technique (45). Pneumocystis jirovecii is non-
261
culturable in routine laboratories and so molecular detection with PCR is commonly
262
used in Europe with a sensitivity of 95-99% (46). Pneumocystis PCR performed on
263
expectorated sputum is also effective for detecting P. jirovecii (47-49), yet
264
infrequently used. In breathless children, PCR on nasopharyngeal aspirates is
265
currently the only realistic means of establishing the diagnosis. In serum, 1,3 beta-D-
266
glucan is detectable in nearly all cases of PCP (19), and if negative, effectively rules
267
out infection. Assuming that 25% of PCP cases are mild, immediate diagnosis and use
8
268
of oral therapy will potentially avoid 100,000 admissions to hospital annually, or even
269
more if the diagnosis is ruled out and patients are not admitted for unnecessary PCP
270
therapy (5). Mild PCP responds well to treatment, and prevents progression to
271
moderate or severe infection.
272
Provision of rapid Pneumocystis diagnostics will enable early diagnosis, allow
273
discontinuation of broad spectrum antibiotics if positive and discontinuation of high
274
dose cotrimoxazole and corticosteroids if negative. Missed PCP diagnoses, obscured
275
by concurrent bacterial infection, will be minimized. Pneumocystis PCR should be
276
widely available for all respiratory samples serving large immunocompromised
277
populations and 1,3 beta-D-glucan in high volume laboratories. These diagnostics will
278
also definitively improve outcome for non-AIDS immunocompromised patients for
279
the same reasons as in AIDS.
280
281
Other clinical scenarios
282
We have not addressed multiple other clinical situations in which precise fungal
283
diagnosis could reduce inappropriate antibacterial prescribing, including cryptococcal
284
meningitis (Figure 4), overtreatment of Candida found in the respiratory tract and
285
urine which can be reduced with the use of better markers of infection, under-
286
diagnosis of invasive aspergillosis in critical care, over-treatment with antifungals of
287
febrile neutropenia in leukaemia, Aspergillus bronchitis in bronchiectasis, allergic,
288
chronic and invasive fungal sinusitis and PCP in HIV-negative patients. In all these
289
clinical settings, inappropriate antibacterial or antifungal prescribing is common,
290
through lack of adequate fungal diagnostic testing. We have also not addressed either
291
rapid detection of antifungal resistant fungi (ie Aspergillus terreus, Candida krusei) or
292
the use of diagnostics to prevent super-infection with high resistance potential fungi,
293
such as Candida glabrata or Rhizopus oryzae. Antifungal resistance is problematic in
294
some settings, demands informed prescribing, therapeutic drug monitoring and
295
development of new antifungal agents (50).
296
297
298
Conclusions
Lack of availability and underuse of non-culture fungal diagnostics results in both
299
over-prescribing and prescription of unduly long courses of antibacterial agents,
300
excess empirical use of antifungal agents, and leaves many millions of patients with
301
undiagnosed fungal infections. It squanders resources. The large scale of the problem,
9
302
even in many of the world’s most advanced medical centers, compromises AMR
303
control. For many countries, Ministries of Health and private providers of healthcare
304
should be actively promoting fungal diagnosis to minimize deaths and morbidity from
305
fungal disease and such efforts will likely have a positive benefit on inappropriate
306
antibacterial usage and support stewardship programs. Public health authorities need
307
to embrace both acute and chronic fungal disease areas of considerable need and seize
308
the opportunity to improve health and preserve what remains of our antimicrobial
309
toolbox.
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
Funding: none.
Possible conflicts of interest.
Dr Denning holds Founder shares in F2G Ltd a University of Manchester spin-out
antifungal discovery company, in Novocyt which markets the Myconostica real-time
molecular assays and has current grant support from the National Institute of Allergy
and Infectious Diseases, National Institute of Health Research, NorthWest Lung
Centre Charity, Medical Research Council, Astellas and the Fungal Infection Trust.
He has acted as a consultant to T2 Biosystems, Astellas, Sigma Tau, Basilea and
Pulmocide. In the last 3 years, he has been paid for talks on behalf of Astellas,
Dynamiker, Gilead, Merck and Pfizer. He is also a member of the Infectious Disease
Society of America Aspergillosis Guidelines and European Society for Clinical
Microbiology and Infectious Diseases Aspergillosis Guidelines groups.
Dr. Perlin serves on scientific advisory boards for Merck, Astellas, Scynexis, Matinas
and Cidara, and he receives grant support from those companies, as well as from the
National Institutes of Health. He is a member of the Clinical & Laboratories
Standards Institute (CLSI) Antifungal Working Group. He has been a paid consultant
by the Gates foundation. He is an inventor on several patents concerning detection of
fungal infections and antifungal drug resistance.
Dr Muldoon has delivered talks on behalf of Pfizer, Gilead, MSD and Astellas, has
received an educational grant from Pfizer .
Dr Colombo has received research grants from Pfizer and Astellas, medical education
grants from Pfizer, MSD, United Medical and Astellas. He has also been a consultant
for MSD, United Medical, and Gilead.
Dr. Chakrabarti has grant support from Department of Biotechnology, Indian Council
Medical Research, Government of India, from Pfizer through Asian Fungal Working
Group and from MSD through Society of Indian Human and Animal Mycologist and
member of European Society for Clinical Microbiology and Infectious Diseases
Aspergillosis, Mucormycosis Guidelines groups
10
348
349
350
351
352
353
354
355
356
357
358
359
360
Dr Richardson is a consultant and gives talks for Basilea, Astellas, MSD, Pfizer,
Gilead Sciences and Associates of Cape Cod.
Dr Sorrell has received investigator driven grants from Pfizer, Merck, Gilead and
have been on their advisory boards in the past.
Author Bio
David Denning is an infectious diseases clinician with expertise in fungal diseases. He is
heavily involved in postgraduate teaching and lectures worldwide. He leads LIFE
(Leading International Fungal Education) (www.LIFE-Worldwide.org) and is President
of the Global Action Fund for Fungal Infections (www.GAFFI.org).
11
361
References
362
1.
O’Neill J, The Review on Antimicrobial Resistance. Antimicrobial Resistance:
363
Tackling a crisis for the health and wealth of nations. December 2014;
364
http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-
365
%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20o
366
f%20nations_1.pdf
367
2.
O. O.T. P. Secretary, Ed. The White House, United States of America, 2015 pp.
368
1-60. www.whitehouse.gov/the-press-office/2015/03/27/fact-sheet-obama-
369
administration-releases-national-action-plan-combat-ant
370
3.
World Health Organisation. Antimicrobial Resistance Global Report on
371
Surveillance 2014.
372
http://www.who.int/drugresistance/documents/AMR_report_Web_slide_set.pdf
373
4.
World Health Organisation. Global Action Plan on Antimicrobial Resistance
374
2015. http://www.who.int/drugresistance/documents/en/ Accessed February 16
375
2016.
376
5.
Yu VL. Guidelines for hospital-acquired pneumonia and health-care-associated
377
pneumonia: a vulnerability, a pitfall, and a fatal flaw. Lancet Infect Dis
378
2011;11:248-52.
379
6.
Global Action Fund for Fungal Infections. ’95-95 by 2025’ Improving outcomes
380
for patients with fungal infections across the world: A Roadmap for the next
381
decade. May 2015. http://www.gaffi.org/roadmap/
382
7.
383
384
Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care
2010;16:445-52.
8.
Tan BH, Chakrabarti A, Li RY, Patel AK, Watcharananan SP, Liu Z, et al; Asia
385
Fungal Working Group (AFWG); Asia Fungal Working Group AFWG.
386
Incidence and species distribution of candidaemia in Asia: a laboratory-based
387
surveillance study. Clin Microbiol Infect. Clin Microbiol Infect 2015;21:946-53.
388
9.
Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D, et al;
389
Australian Candidemia Study. Active surveillance for candidemia, Australia.
390
Emerg Infect Dis 2006;12:1508-16.
12
391
10.
Giacomazzi J, Baethgen L, Carneiro LC, Millington MA, Denning DW,
392
Colombo AL, et al; in association with the LIFE program. The burden of serious
393
human fungal infections in Brazil. Mycoses 2016;59:145-50..
394
11.
Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta
395
DA, et al; Brazilian Network Candidemia Study. Epidemiology of candidemia
396
in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical
397
centers. J Clin Microbiol 2006;44:2816-23.
398
12.
Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al.
399
Incidence, characteristics and outcome of ICU-acquired candidemia in India.
400
Intensive Care Med. 2015 Feb 41;(2):285-95.
401
13. Kami M, Machida U, Okuzumi K, Matsumura T, Mori Si S, Hori A, et al. Effect
402
of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study
403
involving 720 patients with haematological malignancy. Br J Haematol.
404
2002;17:40-6.
405
14.
406
407
Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic
review and meta-analysis. J Clin Microbiol. 2011;49:665-70.
15.
Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al.
408
Performance of Candida real-time polymerase chain reaction, β-D-glucan assay,
409
and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis.
410
2012;54:1240-8.
411
16.
Adams-Chapman I, Bann CM, Das A, Goldberg RN, Stoll BJ, Walsh MC, et al.
412
Neurodevelopmental outcome of extremely low birth weight infants with
413
Candida infection. J Pediatr 2013;163:961-7.
414
17.
Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al;
415
Israeli Candidemia Study Group. Antibiotic exposure as a risk factor for
416
fluconazole-resistant Candida bloodstream infection. Antimicrob Agents
417
Chemother 2012;56:2518-23.
418
419
18. Pfaller MA, Castanheira M. Nosocomial Candidiasis: Antifungal stewardship and
the importance of rapid diagnosis. Med Mycol 2016; 54:1-22.
420
421
13
422
19.
Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, et al.
423
Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci
424
pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review
425
and meta-analysis. J Clin Microbiol 2012;50:7-15.
426
20.
Martínez-Jiménez MC, Muñoz P, Valerio M, Vena A, Guinea J, Bouza E.
427
Combination of Candida biomarkers in patients receiving empirical antifungal
428
therapy in a Spanish tertiary hospital: a potential role in reducing the duration of
429
treatment. J Antimicrob Chemother 2015;70:3107-15.
430
21.
Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ,
431
Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of
432
candidemia in whole blood: a clinical trial. Clin Infect Dis 2015;60:892-9.
433
22.
Richardson R, Muldoon E. Compliance with candidaemia guidelines in the ICU
434
– a UK tertiary referral teaching hospital experience. Abtracts in: European
435
Conference on Clinical Microbiology and Infectious Diseases, Copenhagen.
436
2015 April 25-27. Abstract P0215.
437
www.escmid.org/escmid_library/online_lecture_library/?search=1&current_pag
438
e=1&search_term=muldoon
439
23.
Walker B, Powers-Fletcher MV, Schmidt RL, Hanson KE. A cost effectiveness
440
analysis of multiplex PCR with magnetic resonance detection versus
441
empiric or blood culture directed therapy for the management of suspected
442
candidemia. J Clin Microbiol 2016;54:718-26.
443
24.
444
445
Ruhnke M. Antifungal stewardship in invasive Candida infections. Clin
Microbiol Infect 2014;20 (Suppl 6):11-8.
25.
Chakaya J, Kirenga B, Getahun H. Long term complications after completion of
446
pulmonary tuberculosis treatment: A quest for a public health approach. J Clin
447
Tubercul Myco Dis 2016; 3:10-12.
448
26.
449
450
Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary
aspergillosis as a sequel to tuberculosis. Bull WHO 2011;89:864-72.
27.
Sterling T, Jenkins C, Jayathilake K, Gotuzzo E, Veloso V, Cortes CP, Padgett
451
D, Crabtree-Ramirez B, Shepherd BE, McGowan C. Culture-negative TB is
452
associated with increased mortality in HIV-Infected persons. Annual
14
453
Conference on Retroviruses and Opportunistic Infections (CROI) 2015
454
February 23-26, Seattle, Washington. Abstr 833.
455
www.croiconference.org/sessions/culture-negative-tb-associated-increased-
456
mortality-hiv-infected-persons
457
28.
Chu C-M, Woo PCY, Chong KTK, Leung WS, Chan VL, Yuen KY.
458
Association of presence of Aspergillus antibodies with hemoptysis in patients
459
with old tuberculosis or bronchiectasis but no radiologically visible mycetoma. J
460
Clin Microbiol 2004; 42: 665–669.
461
29.
Denning DW, Cadranel J, Beigelman-Aubry C, Ader, F, Chakrabarti A, Blot S,
462
et al. Chronic pulmonary aspergillosis – Rationale and clinical guidelines for
463
diagnosis and management. Eur Resp J 2016;47:45-68.
464
30.
Page ID, Richardson MD, Denning DW. Comparative diagnostic performance
465
of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary
466
aspergillosis. J Infect 2016;72:240-9.
467
31.
Dumollard C, Bailly S, Perriot S, Brenier-Pinchart MP, Saint-Raymond C,
468
Camara B, Gangneux JP, Persat F, Valot S, Grenouillet F, Pelloux H, Pinel C,
469
Cornet M. Prospective evaluation of a new Aspergillus IgG enzyme
470
immunoassay kit for diagnosis of chronic and allergic pulmonary aspergillosis. J
471
Clin Microbiol 2016;54:1236-42.
472
32.
Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, Hayakawa H, Chida K.
473
Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir
474
Med 2012;106:724-9.
475
33.
Hedayati MT, Azimi Y, Droudinia A, Mousavi B, Khalilian A, Hedayati N,
476
Denning DW. Prevalence of chronic pulmonary aspergillosis in patients with
477
tuberculosis from Iran. Eur J Clin Microbiol Infect Dis 2015;34:1759-65.
478
34.
World Health Organization Global Tuberculosis Report 2014
479
http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf
480
Accessed December 2015.
481
482
35.
Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al.
Global strategy for the diagnosis, management, and prevention of chronic
15
483
obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit
484
Care Med 2013;187: 347–365.
485
29.
486
36.
López-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM; European COPD
487
Audit team. Antibiotic prescription for COPD exacerbations admitted to
488
hospital: European COPD audit. PLoS One 2015;10:e0124374.
489
37.
Huerta A, Soler N, Esperatti M, Guerrero M, Menendez R, Gimeno A, et al.
490
Importance of Aspergillus spp. isolation in Acute exacerbations of severe
491
COPD: prevalence, factors and follow-up: the FUNGI-COPD study. Respir Res
492
2014;15:17.
493
38.
Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, et al.
494
Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease:
495
incidence, risk factors, and outcome. Clin Microbiol Infect 2010;16:870-7.
496
39.
Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary
497
aspergillosis in patients with chronic obstructive pulmonary disease: a case
498
control study from China. Clin Microbiol Infect 2012;18:403-8.
499
40. Tan WC, Seale P, Ip M, Shim YS, Chiang CH, Ng TP, Abisheganadan J,
500
Charoenratanakul S, DeGuia T, Mahayiddin A, Mangunnegoro H, Xu YJ,
501
Zhong NS. Trends in COPD mortality and hospitalizations in countries and
502
regions of Asia-Pacific. Respirology 2009;14:90-7.
503
41.
Lim S, Lam DC, Muttalif AR, Yunus F, Wongtim S, Lan le TT, et al. Impact of
504
chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the
505
EPIC Asia population-based survey. Asia Pac Fam Med 2015;14:4.
506
42.
Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi
507
and allergic lower respiratory tract diseases. J Allergy Clin Immunol
508
2012;129:280-91.
509
43.
Lowe DM, Rangaka MX, Gordon F, James CD, Miller RF. Pneumocystis
510
jirovecii pneumonia in tropical and low and middle income countries: a
511
systematic review and meta-regression. PLoS One 2013;8:e69969.
16
512
44.
Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-
513
sulfamethoxazole in patients with the acquired immunodeficiency syndrome.
514
Ann Intern Med 1984;100:495-9.
515
45.
Procop GW, Haddad S, Quinn J, Wilson ML, Henshaw NG, Reller LB, et al.
516
Detection of Pneumocystis jiroveci in respiratory specimens by four staining
517
methods. J Clin Microbiol 2004;42:3333-5.
518
46.
Fan L-C, Lu H-W, Cheng K-B Li H-P, Xu J-F. Evaluation of PCR in
519
bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii
520
pneumonia: a bivariate meta-analysis and systematic review. PLoS One
521
2013;8:e73099.
522
47.
Rafanan AL, Klevjer-Anderson P, Metersky ML. Pneumocystis carinii
523
pneumonia diagnosed by non-induced sputum stained with a direct fluorescent
524
antibody. Ann Clin Lab Sci 1998;28: 99-103.
525
48.
Choe PG, Kang YM, Kim G, Park WB, Park SW, Kim HB, et al. Diagnostic
526
value of direct fluorescence antibody staining for detecting Pneumocystis
527
jirovecii in expectorated sputum from patients with HIV infection. Med Mycol
528
2014;52:326-30.
529
49.
Nowaseb V, Gaeb E, Fraczek MG, Richardson MD, Denning DW. Frequency
530
of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia. J
531
Infect Dev Ctries. 2014;8:349-57.
532
533
50.
Denning DW, Bromley MJ. Infectious Disease. How to bolster the antifungal
pipeline. Science 2015;347:1414-6.
534
535
536
17
537
538
539
Figure legends
540
Chest radiograph showing bilateral upper lobe chronic pulmonary aspergillosis, easily
541
mistaken for pulmonary tuberculosis. The blue arrows show the areas of abnormality
542
in both apices – some pleural thickening and opacification, which is similar although
543
slightly more obvious to the findings in pulmonary tuberculosis. The orange arrow
544
shows the trachea pulled to one side by the contraction and fibrosis on that side.
545
Image from David Denning, all rights reserved.
546
Figure 2:
547
CT scan of the thorax showing chronic pulmonary histoplasmosis with bilateral
548
cavitary infiltrates resembling pulmonary tuberculosis, coccidioidomycosis,
549
paracoccidioidomycosis and aspergillosis. The abnormal areas are shown by arrows.
550
Image from Arnaldo Colombo, all rights reserved.
551
Figure 3:
552
Chest radiograph showing early subtle abnormalities in both lower lung fields of PCP
553
in a new diagnosis of AIDS unsuspected in a married man aged 63 years. The two
554
boxes of magnification illustrate normal lung lung (upper) and infiltrates adjacent to
555
and behind the heart and overlain by rib (lower). Similar differences between the
556
upper and lower lobes are seen in the other lung. Image from David Denning, all
557
rights reserved.
558
Figure 4:
559
An ulcerative skin lesion misdiagnosed for weeks as a bacterial infection, which
560
showed Cryptococccus neoformans on biopsy. Image from Arnaldo Colombo, all
561
rights reserved.
Figure 1:
562
18